| Literature DB >> 23991241 |
Saul N Rajak1, Esmael Habtamu, Helen A Weiss, Amir B Kello, Bayeh Abera, Mulat Zerihun, Teshome Gebre, Clare E Gilbert, Peng T Khaw, Paul M Emerson, Matthew J Burton.
Abstract
BACKGROUND: Over 1.2 million people are blind from trachomatous trichiasis (TT). Lid rotation surgery is the mainstay of treatment, but recurrence rates can be high. We investigated the outcomes (recurrence rates and other complications) of posterior lamellar tarsal rotation (PLTR) surgery, one of the two most widely practised TT procedures in endemic settings. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2013 PMID: 23991241 PMCID: PMC3749971 DOI: 10.1371/journal.pntd.0002392
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Demographic and pre-operative clinical characteristics of participants, sub-divided by major and minor trichiasis.
| Minor TT (<6 lashes) | Major TT (>5 lashes) | |||
| Eyes | 650 | 650 | ||
| Sex (female) | 448 | (68.9%) | 508 | (78.2%) |
| Age | ||||
| 18–30 | 69 | (10.6%) | 48 | (7.4%) |
| 30–39 | 113 | (17.4%) | 123 | (18.9%) |
| 40–49 | 156 | (24.0%) | 186 | (28.6%) |
| 50–59 | 160 | (24.6%) | 167 | (25.7%) |
| 60–69 | 112 | (17.2%) | 93 | (14.3%) |
| 70+ | 40 | (6.2%) | 33 | (5.1%) |
| mean (sd, 95% C.I.) | 49.9 | (14.4, 48.8–51.0) | 49.7 | (12.9, 48.7–50.7) |
| Illiterate | 581 | (89.4%) | 617 | (94.9%) |
| BMI, mean (sd, 5% CI) | 19.9 | (2.3, 19.7–20.1) | 20.1 | (2.5, 19.9–20.3) |
| Right eye | 319 | (49.1%) | 321 | (49.4%) |
| Best corrected logMAR VA in study eye | ||||
| −0.2–0.3 | 243 | (37.7%) | 193 | (30.0%) |
| 0.3–0.7 | 261 | (40.5%) | 248 | (38.5%) |
| 0.7–1.1 | 83 | (12.9%) | 104 | (16.2%) |
| 1.1–2.0 | 19 | (2.9%) | 29 | (4.5%) |
| CF/HM/PL | 30 | (4.6%) | 62 | (9.6%) |
| NPL | 9 | (1.4%) | 8 | (1.2%) |
| Not measurable | 5 | 6 | ||
| Entropion grade | ||||
| 0 | 276 | (42.5%) | 51 | (7.9%) |
| 1 | 258 | (39.7%) | 159 | (24.5%) |
| 2 | 113 | (17.4%) | 242 | (37.2%) |
| 3 | 3 | (0.5%) | 119 | (18.3%) |
| 4 | 0 | (0.0%) | 79 | (12.2%) |
| Trichiasis (number of lashes) (median: 1) | ||||
| None - epilating | 124 | (19.1%) | 106 | (16.3%) |
| 1–5 | 526 | (80.9%) | 253 | (38.9%) |
| 6–9 | 0 | (0.0%) | 152 | (23.4%) |
| 10–19 | 0 | (0.0%) | 89 | (13.7%) |
| 20+ | 0 | (0.0%) | 50 | (7.7%) |
| Lash location | ||||
| None – epilating | 124 | (19.1%) | 106 | (16.3%) |
| Corneal +/− peripheral | 462 | (71.1%) | 524 | (80.6%) |
| Peripheral only | 64 | (9.9%) | 20 | (3.1%) |
| Lash type | ||||
| None (epilating) | 124 | (19.1%) | 106 | (16.3%) |
| Metaplastic only | 299 | (46.0%) | 206 | (31.7%) |
| Misdirected only | 165 | (25.4%) | 83 | (12.8%) |
| Metaplastic and misdirected | 59 | (9.1%) | 67 | (10.3%) |
| Entropic +/− aberrant | 3 | (0.5%) | 188 | (28.9%) |
| Lower lid TT | ||||
| Present | 70 | (10.8%) | 88 | (13.5%) |
| Corneal opacity | ||||
| None (C0) | 345 | (53.1%) | 187 | (28.8%) |
| Peripheral (C1) | 168 | (25.9%) | 181 | (27.9%) |
| Off centre faint (C2a) | 76 | (11.7%) | 147 | (22.6%) |
| Off centre dense (C2b) | 9 | (1.4%) | 26 | (4.0%) |
| Central faint (C2c) | 30 | (4.6%) | 63 | (9.7%) |
| Central dense (C2d) | 11 | (1.7%) | 18 | (2.8%) |
| Total central dense (C3) | 10 | (1.5%) | 22 | (3.4%) |
| Phthisis (C4) | 1 | (0.2%) | 6 | (0.9%) |
| Papillary inflammation | ||||
| None (P0) | 52 | (8.0%) | 52 | (8.0%) |
| Mild (P1) | 248 | (38.2%) | 183 | (28.2%) |
| Moderate (P2) | 297 | (45.7%) | 312 | (48.1%) |
| Severe (P3) | 53 | (8.2%) | 102 | (15.7%) |
| Conjunctival scarring | ||||
| None (C0) | 3 | (0.5%) | 0 | (0.0%) |
| Mild (C1) | 60 | (9.2%) | 18 | (2.8%) |
| Moderate (C2) | 508 | (78.2%) | 400 | (61.6%) |
| Severe (C3) | 79 | (12.2%) | 231 | (35.6%) |
| Conjunctivalisation Grade | ||||
| 0 | 7 | (1.1%) | 2 | (0.3%) |
| 1 | 18 | (2.8%) | 5 | (0.8%) |
| 2 | 165 | (25.4%) | 96 | (14.8%) |
| 3 | 460 | (70.8%) | 545 | (84.1%) |
| Lagophthalmos | 10 | (1.5%) | 20 | (3.1%) |
Despite having less than 5 lashes actually touching the globe at the time of examination, these individuals had clinical evidence of epilation of trichiatic lashes, such that the total of trichiatic lashes would have been greater than 5 had they not epilated.
Patient unable to co-operate with visual acuity measurement.
Figure 1Conjunctivalisation of the lid margin.
1a: The lid margin at baseline showing marked conjunctivalisation; the Meibomian gland orifices are completely surrounded by conjunctival-type surface. 1b: The lid margin of the same participant at the two-year follow-up; the conjunctival surface appears to have receded and the Meibomian gland orifices are surrounded by skin with a normal appearance.
Risk of trichiasis recurrence and severity, subdivided by baseline severity.
| Baseline TT Severity | ||||||
| Minor TT | Major TT | Total | ||||
|
| ||||||
| 6 | 52/615 | (8.5%) | 120/587 | (20.4%) | 172/1202 | (14.3%) |
| 12 | 23/622 | (3.7%) | 37/612 | (6.1%) | 60/1234 | (4.9%) |
| 18 | 22/620 | (3.6%) | 34/622 | (5.5%) | 56/1242 | (4.5%) |
| 24 | 11/614 | (1.8%) | 16/619 | (2.6%) | 27/1233 | (2.2%) |
|
|
|
|
|
|
|
|
|
| ||||||
| None | 533 | (83.2%) | 428 | (67.4%) | 961 | (75.3%) |
| Minor | 104 | (16.2%) | 169 | (26.6%) | 273 | (21.4%) |
| Major (at 1 or more follow-ups) | 4 | (0.6%) | 38 | (6.0%) | 42 | (3.3%) |
|
|
|
|
| |||
|
| ||||||
| Right | 49/314 | (15.6%) | 102/316 | (32.3%) | 151/630 | (24.0%) |
| Left | 59/327 | (18.0%) | 105/319 | (32.9%) | 164/646 | (25.4%) |
|
|
|
|
| |||
|
| ||||||
| >5 more lashes at 24 m | 0 | (0.0%) | 2 | (1.0%) | 2 | (0.7%) |
| 1–5 more lashes at 24 m | 2 | (1.9%) | 12 | (6.1%) | 14 | (4.6%) |
| Same number lashes at 24 m | 26 | (24.3%) | 35 | (17.7%) | 61 | (20.0%) |
| 1–5 fewer lashes at 24 m | 79 | (73.8%) | 66 | (33.3%) | 145 | (47.5%) |
| 6–20 fewer lashes at 24 m | 0 | (0.0%) | 69 | (34.9%) | 69 | (22.6%) |
| >20 fewer lashes at 24 m | 0 | (0.0%) | 14 | (7.1%) | 14 | (4.6) |
|
|
|
|
|
|
|
|
|
| ||||||
| No lashes (epilating) | 11/123 | (8.9%) | 34/101 | (33.7%) | 45/224 | (20.1%) |
| Metaplastic lashes only | 54/293 | (18.4%) | 64/200 | (32.0%) | 118/493 | (23.9%) |
| Misdirected lashes only | 27/164 | (16.5%) | 16/83 | (19.3%) | 43/247 | (17.4%) |
| Aberrant lashes | 15/58 | (25.9%) | 14/65 | (21.5%) | 29/123 | (23.6%) |
| Entropic +/− aberrant lashes | 1/3 | (33.3%) | 79/186 | (42.5%) | 80/189 | (42.3%) |
Number of individuals seen on at least one follow-up.
Aberrant lashes = either metaplastic or misdirected.
(a) Incident recurrence at each time-point. (b) Severity of the recurrence. (c) Recurrence rates by eye. (d) Change in the number of lashes between baseline and 24 months. (e) Recurrence by type of lash at baseline.
Baseline severity of cases operated (case mix), under-correction and overall trichiasis recurrence rates by surgeon.
| Surgeon ID | Total | |||||||||||
| 1 | 2 | 3 | 4 | 5 | ||||||||
|
| ||||||||||||
| Minor | 186 | (49.5%) | 149 | (52.7%) | 167 | (55.1%) | 118 | (45.4%) | 30 | (38.5%) | 650 | (50%) |
| Major | 190 | (50.5%) | 134 | (47.4%) | 136 | (44.9%) | 142 | (54.6%) | 48 | (61.5%) | 650 | (50%) |
| Total | 376 | 283 | 303 | 260 | 78 | 1300 | ||||||
|
| ||||||||||||
| 11 | (2.9%) | 9 | (3.2%) | 5 | (1.7%) | 7 | (2.7%) | 8 | (10.3%) | 40 | (3.1%) | |
|
| ||||||||||||
| Yes | 75 | (20.3%) | 88 | (32.0%) | 67 | (22.3%) | 45 | (17.7%) | 40 | (52.6%) | 315 | (24.7%) |
| Total Seen | 370 | 275 | 301 | 254 | 76 | 1276 | ||||||
Denominator: total number of patients operated by that surgeon.
Denominator: participants seen on at least one follow up occasion.
Univariable analysis and multivariable logistic regression model for baseline associations with any TT recurrence.
| Variable | Univariable Analysis | Multivariable Analysis | ||||
| OR | 95% CI | p Value | OR | 95% CI | p Value | |
| Female | 1.11 | 0.83–1.49 | 0.47 | |||
| Age>40 | 1.65 | 1.21–2.24 | 0.002 | 1.59 | 1.14–2.20 | 0.006 |
| Literate | 0.79 | 0.48–1.29 | 0.35 | |||
| BMI<18 | 0.70 | 0.51–0.95 | 0.024 | 0.79 | 0.56–1.09 | 0.15 |
| Major TT at baseline | 2.39 | 1.83–3.11 | <0.001 | 1.93 | 1.43–2.60 | <0.001 |
| Eye (Right) | 1.08 | 0.84–1.39 | 0.56 | |||
| Baseline entropion severity | 1.35 | 1.21–1.51 | <0.001 | |||
| Surgeon | <0.001 | <0.001 | ||||
| 1 | 1.18 | 0.78–1.78 | 1.23 | 0.81–1.88 | ||
| 2 | 2.19 | 1.45–3.29 | 2.46 | 1.60–3.77 | ||
| 3 | 1.33 | 0.87–2.03 | 1.49 | 0.9762.30 | ||
| 5 | 5.16 | 2.97–8.98 | 5.18 | 2.90–9.26 | ||
| Baseline lash type | <0.001 | <0.001 | ||||
| Metaplastic only | 1.25 | 0.85–1.84 | 1.27 | 0.85–1.90 | ||
| Misdirected only | 0.84 | 0.53–1.33 | 0.89 | 0.55–1.43 | ||
| Metaplastic and misdirected | 1.23 | 0.72–2.08 | 1.10 | 0.63–1.92 | ||
| Entropic +/− aberrant | 2.92 | 1.89–4.51 | 1.99 | 1.23–3.20 | ||
| Purulent discharge at baseline | 1.86 | 1.17–2.95 | 0.009 | 1.21 | 0.73–2.02 | 0.46 |
| Mucus discharge at baseline | 1.39 | 0.63–3.06 | 0.42 | |||
| Baseline Inflammation (P2/P3) | 1.37 | 1.06–1.79 | 0.018 | 1.23 | 0.93–1.63 | 0.15 |
Entropion treated as a linear variable (LR test for linearity: p = 0.07).
Entropion dropped from multivariable model as strongly linked to baseline lash type.
Compared to surgeon 4 who had the lowest recurrence rate. Likelihood ratio used to calculate p value for association between surgeon and recurrent TT.
Compared to group with all trichiatic lashes epilated. Likelihood ratio used to calculate p value for association between lash type and recurrent TT.
Frequency and risk of post-operative complications, stratified by baseline disease severity. Trichiasis recurrence rates in eyes with the specific complication.
| Baseline TT Severity | ||||||
| Minor TT | Major TT | Total | ||||
|
| ||||||
| Bleeding | 11 | (1.7%) | 6 | (0.9%) | 17 | (1.3%) |
|
| ||||||
| TT recurrence at 7–10 days | 5 | (0.8%) | 24 | (3.8%) | 29 | (2.3%) |
| Overcorrection | 2 | (0.3%) | 4 | (0.6%) | 6 | (0.5%) |
| Infection/erythematous swelling/conjunctivitis | 3 | (0.5%) | 6 | (0.9%) | 10 | (0.8%) |
| Infection & undercorrection | 1 | (0.2%) | 0 | (0.0%) | 1 | (0.1%) |
| Bleeding | 3 | (0.5%) | 1 | (0.2%) | 4 | (0.3%) |
|
| ||||||
| Granuloma | 18 | (2.9%) | 51 | (8.7%) | 69 | (5.7%) |
| Notching | 86 | (14.0%) | 70 | (11.9%) | 156 | (13.0%) |
| Residual suture fragments | 7 | (1.1%) | 15 | (2.6%) | 22 | (1.8%) |
| Lid abscess | 1 | (0.2%) | 0 | (0.0%) | 1 | (0.1%) |
Univariable and multivariable associations between recurrent TT and intra- and post-operative complications.
| Variable | Univariable Analysis | Multivariable Analysis | ||||
| OR | 95% CI | p Value | OR | 95% CI | p Value | |
| Intra-operative haemorrhage | 0.65 | 0.18–2.27 | 0.50 | |||
| Trichiasis at 7–10 days | 10.25 | 4.33–24.23 | <0.001 | 10.44 | 4.20–25.95 | <0.001 |
| 7–10 day overcorrection | 1.63 | 0.30–8.95 | 0.57 | |||
| 7–10 day infection/swelling/conjunctivitis | 1.63 | 0.41–6.56 | 0.49 | |||
| Granuloma | 0.39 | 0.19–0.83 | 0.014 | 0.31 | 0.13–0.74 | 0.008 |
| Notching | 0.44 | 0.28–0.72 | 0.001 | 0.52 | 0.32–0.85 | 0.009 |
| Residual suture fragment(s) | 1.47 | 0.59–3.63 | 0.409 | |||
| Inflammation (P2/P3) at 12 months | 1.70 | 1.14–2.54 | 0.01 | 1.64 | 1.06–2.53 | 0.027 |
Univariable and multivariable intra and post-operative associations for granuloma and notching.
| Variable | Granuloma | Notching | ||||||||||
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||||||
| OR | 95% CI | p Value | OR | 95% CI | p Value | OR | 95% CI | p Value | OR | 95% CI | p Value | |
| Recurrence | 0.39 | 0.19–0.83 | 0.014 | 0.33 | 0.15–0.71 | 0.005 | 0.39 | 0.19–0.83 | 0.014 | 0.49 | 0.30–0.81 | 0.005 |
| >5 lashes at baseline | 3.16 | 1.82–5.47 | <0.001 | 4.07 | 2.16–7.67 | <0.001 | 0.83 | 0.59–1.17 | 0.29 | |||
| Baseline entropion severity | 1.17 | 0.95–1.44 | 0.15 | 0.86 | 0.66–1.11 | 0.25 | 0.90 | 0.77–1.05 | 0.18 | 0.96 | 0.82–1.13 | 0.35 |
| Surgeon | 0.0267 | <0.001 | <0.001 | 0.002 | ||||||||
| 1 | 2.23 | 1.06–4.71 | 0.62 | 0.30–1.27 | 2.20 | 1.28–3.79 | 2.02 | 1.17–3.49 | ||||
| 2 | 1.31 | 0.56–3.09 | 0.44 | 0.20–0.93 | 1.0 | n/a | 1.0 | |||||
| 3 | 1.0 | n/a | 1.0 | n/a | 1.76 | 0.99–3.13 | 1.62 | 0.91–2.91 | ||||
| 4 | 2.42 | 1.11–5.27 | 0.97 | 0.52–1.81 | 2.71 | 1.55–4.74 | 2.47 | 1.40–4.35 | ||||
| 5 | 0.41 | 0.05–3.29 | 0.18 | 0.023–1.39 | 0.37 | 0.084–1.63 | 0.41 | 0.09–1.83 | ||||
| Inflammation at baseline (P2/P3) | 2.14 | 1.29–3.57 | 0.003 | 2.23 | 1.33–3.78 | 0.003 | 0.67 | 0.47–0.94 | 0.022 | 0.75 | 0.53–1.07 | |
| Female | 0.73 | 0.44–1.23 | 0.24 | 0.79 | 0.55–1.14 | 0.21 | ||||||
| Age>40 yrs | 0.80 | 0.47–1.35 | 0.41 | 2.06 | 1.32–3.20 | 0.001 | 1.99 | 1.26–3.12 | 0.003 | |||
| BMI>18 | 1.44 | 0.72–2.86 | 0.30 | 0.65 | 0.44–0.96 | 0.032 | 0.65 | 0.43–0.97 | 0.034 | |||
Surgeon and granuloma association: other surgeons compared to surgeon 3. Surgeon 5 had the lowest granuloma rate but performed substantially fewer procedures than the other surgeons. Surgeon 3 had the second lowest rate.
Notching and granuloma association: other surgeons compared to surgeon 2. Surgeon 5 had the lowest notching rate, but performed substantially fewer procedures than the other surgeons. Surgeon 2 had the second lowest rate.
The effect of surgery on clinical characteristics at 12 and 24 months subdivided by baseline severity.
| Baseline | 12 months | 24 months | ||||||||||||
| Clinical Feature | Minor at baseline | Major at baseline | Total | Minor at baseline | Major at baseline | Total | ||||||||
| Eyes | 1300 | 620 | 608 | 1228* | 613 | 609 | 1222 | |||||||
| Entropion grade | ||||||||||||||
| 0 | 327 | (25.2%) | 598 | (96.5%) | 550 | (90.5%) | 1148 | (93.5%) | 588 | (95.9%) | 538 | (88.3%) | 1126 | (92.1%) |
| 1 | 417 | (32.1%) | 19 | (3.1%) | 34 | (5.6%) | 53 | (4.3%) | 18 | (2.9%) | 44 | (7.2%) | 62 | (5.1%) |
| 2 | 355 | (27.3%) | 3 | (0.5%) | 16 | (2.6%) | 19 | (1.6%) | 7 | (1.1%) | 22 | (3.6%) | 29 | (2.4%) |
| 3 | 122 | (9.4%) | 0 | (0.0%) | 6 | (1.0%) | 6 | (0.5%) | 0 | (0.0%) | 4 | (0.7%) | 4 | (0.3%) |
| 4 | 79 | (6.1%) | 0 | (0.0%) | 2 | (0.3%) | 2 | (0.2%) | 0 | (0.0%) | 1 | (0.2%) | 1 | (0.1%) |
| Conjunctivalisation Grade | ||||||||||||||
| 0 | 9 | (0.7%) | 115 | (18.6%) | 84 | (13.8%) | 199 | (16.2%) | 74 | (12.1%) | 55 | (9.0%) | 129 | (10.6%) |
| 1 | 23 | (1.8%) | 88 | (14.2%) | 88 | (14.5%) | 176 | (14.3%) | 63 | (10.3%) | 68 | (11.2%) | 131 | (10.7%) |
| 2 | 261 | (20.1%) | 258 | (41.6%) | 249 | (40.9%) | 507 | (41.3%) | 309 | (50.4%) | 274 | (45.0%) | 583 | (47.7%) |
| 3 | 1005 | (77.4%) | 159 | (25.7%) | 187 | (13.8%) | 346 | (28.2%) | 167 | (27.2%) | 212 | (34.8%) | 379 | (31.1%) |
Total number of participants seen at 12 and 24 months. On occasion, a specific part of the examination was not possible for a particular participant; therefore the total for each examination characteristic is not always identical to these total figures.